0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Visual hallucinations are common in Parkinson’s disease (PD) and associated with worse outcomes. Large-scale network imbalance is seen in PD-associated hallucinations, but mechanisms remain unclear. As the thalamus is critical in controlling cortical networks, structural thalamic changes could underlie network dysfunction in PD hallucinations.

          Methods

          We used whole-brain fixel-based analysis and cortical thickness measures to examine longitudinal white and grey matter changes in 76 patients with PD (15 hallucinators, 61 non-hallucinators) and 26 controls at baseline, and after 18 months. We compared white matter and cortical thickness, adjusting for age, gender, time-between-scans and intracranial volume. To assess thalamic changes, we extracted volumes for 50 thalamic subnuclei (25 each hemisphere) and mean fibre cross-section (FC) for white matter tracts originating in each subnucleus and examined longitudinal change in PD-hallucinators versus non-hallucinators.

          Results

          PD hallucinators showed white matter changes within the corpus callosum at baseline and extensive posterior tract involvement over time. Less extensive cortical thickness changes were only seen after follow-up. White matter connections from the right medial mediodorsal magnocellular thalamic nucleus showed reduced FC in PD hallucinators at baseline followed by volume reductions longitudinally. After follow-up, almost all thalamic subnuclei showed tract losses in PD hallucinators compared with non-hallucinators.

          Interpretation

          PD hallucinators show white matter loss particularly in posterior connections and in thalamic nuclei, over time with relatively preserved cortical thickness. The right medial mediodorsal thalamic nucleus shows both connectivity and volume loss in PD hallucinations. Our findings provide mechanistic insights into the drivers of network imbalance in PD hallucinations and potential therapeutic targets.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: not found

          N4ITK: improved N3 bias correction.

          A variant of the popular nonparametric nonuniform intensity normalization (N3) algorithm is proposed for bias field correction. Given the superb performance of N3 and its public availability, it has been the subject of several evaluation studies. These studies have demonstrated the importance of certain parameters associated with the B-spline least-squares fitting. We propose the substitution of a recently developed fast and robust B-spline approximation routine and a modified hierarchical optimization scheme for improved bias field correction over the original N3 algorithm. Similar to the N3 algorithm, we also make the source code, testing, and technical documentation of our contribution, which we denote as "N4ITK," available to the public through the Insight Toolkit of the National Institutes of Health. Performance assessment is demonstrated using simulated data from the publicly available Brainweb database, hyperpolarized (3)He lung image data, and 9.4T postmortem hippocampus data.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

            Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications. © 2010 Movement Disorder Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation

              MRtrix3 is an open-source, cross-platform software package for medical image processing, analysis and visualisation, with a particular emphasis on the investigation of the brain using diffusion MRI. It is implemented using a fast, modular and flexible general-purpose code framework for image data access and manipulation, enabling efficient development of new applications, whilst retaining high computational performance and a consistent command-line interface between applications. In this article, we provide a high-level overview of the features of the MRtrix3 framework and general-purpose image processing applications provided with the software.
                Bookmark

                Author and article information

                Journal
                J Neurol Neurosurg Psychiatry
                J Neurol Neurosurg Psychiatry
                jnnp
                jnnp
                Journal of Neurology, Neurosurgery, and Psychiatry
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0022-3050
                1468-330X
                February 2022
                28 September 2021
                : 93
                : 2
                : 169-179
                Affiliations
                [1 ] departmentDementia Research Centre , University College London , London, UK
                [2 ] departmentHuntington’s Disease Centre , UCL Institute of Neurology , London, UK
                [3 ] departmentReta Lila Weston Institute , Institute of Neurology , London, UK
                [4 ] departmentWellcome Centre for Human Neuroimaging , University College London , London, UK
                [5 ] departmentMovement Disorders Consortium , National Hospital for Neurology and Neurosurgery , London, UK
                Author notes
                [Correspondence to ] Dr Angeliki Zarkali, Dementia Research Centre, University College London, London, WC1N 3AR, UK; a.zarkali@ 123456ucl.ac.uk
                Author information
                http://orcid.org/0000-0002-5092-6325
                Article
                jnnp-2021-326630
                10.1136/jnnp-2021-326630
                8785065
                34583941
                6b867b92-4b27-465c-8136-de1fc957a4a8
                © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

                History
                : 15 March 2021
                : 25 August 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100002283, Alzheimer’s Research UK;
                Award ID: 2018B-001
                Funded by: Wellcome Clinical Research Career Development Fellowship;
                Award ID: 205167/Z/16/Z
                Funded by: FundRef http://dx.doi.org/10.13039/501100000272, National Institute for Health Research;
                Funded by: FundRef http://dx.doi.org/10.13039/100010269, Wellcome;
                Award ID: 205167/Z/16/Z
                Categories
                Neurodegeneration
                1506
                Original research
                Custom metadata
                unlocked

                Surgery
                parkinson's disease,hallucinations
                Surgery
                parkinson's disease, hallucinations

                Comments

                Comment on this article